“There are so many pressures” in community oncology, says Johnetta Blakely, MD -TennesseeOncology bit.ly/3UQqEOr #COA2024

Results from the CAPItello-291 trial prompt update to the ASCO Rapid Recommendation Guideline on endocrine and targeted therapy for patients with hormone receptor–positive, HER2-negative metastatic breast cancer. bit.ly/49nSzJB #BCSM

The number of medical oncologists is ⬆️. The number of oncology practices is ⬇️. bit.ly/3VyOWNU via JCO Oncology Practice

Breakthrough in LS- #SCLC treatment: ADRIATIC trial shows AstraZeneca's durvalumab (Imfinzi) significantly enhances survival after chemoradiotherapy. Marking a potential shift in treatment standards. 🚀🔬 bit.ly/44w6AEn #ASCO24

Patients with #MultipleMyeloma treated in the real world had 44% worse PFS and 75% worse OS than patients treated on clinical trials, according to a pooled analysis of efficacy versus effectiveness for seven MM regimens. bit.ly/3xT13vq #hematology

Newly published article highlights a promising KRAS G12C targeted therapy for advanced NSCLC, offering potential advancements in treatment options. Valuable read for #OncTwitter . bit.ly/3UkLT9S

.ASTRO strongly urges a return to real-time, direct supervision for all #RadOnc services at all care sites. bit.ly/3vrkqee

Breakthrough in LS- #SCLC treatment: ADRIATIC trial shows AstraZeneca's durvalumab (Imfinzi) significantly enhances survival after chemoradiotherapy. Marking a potential shift in treatment standards. 🚀🔬 bit.ly/44w6AEn #ASCO24

Lack of key data in EGFR mutant #NSCLC poses a challenge for oncologists. bit.ly/3Ugxknx via Eric K. Singhi, MD

❇️ USPSTF now recommends that women aged 40 to 74 years at normal risk for breast cancer undergo screening #mammography every two years versus every year. The recommended age to start mammography is 40 as opposed to 50. bit.ly/4di3KXv #BCSM

The shortage of the oncology workforce is real.bit.ly/49xbZvJ

Guideline panels, professional societies, and medical journals should set stronger rules to prevent bias stemming from financial conflicts of interest in oncology. bit.ly/44puTnx via JCO Oncology Practice Editorial

Oncologists are raising concerns about crossover in Clinical Trials, specifically about its “problematic” use or absence. Some experts say that changes should be mandated to avoid undue harm. via H. Jack West, MD Bishal Gyawali Eddie Cliff obroncology.com/article/contro…

Although some oncologists may have fears about potential litigation associated with active surveillance in cancer care, a new study found no successful claims. bit.ly/3UA4gZx

5 Multiple Myeloma drugs that are transforming care. bit.ly/4a4zflc #MMSM

Hospital retains its top U.S. News & World Report cancer care ranking. bit.ly/3JDWh7F

✅ Tivdak gets FDA approval for recurrent or metastatic cervical cancer in patients whose disease has progressed after chemotherapy. bit.ly/4bbOf25

✳️ FDA grants accelerated approval to Ojemda for R/R pediatric low-grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 mutation. bit.ly/3walTpx

Attention oncologists: Protect your practice against income loss due to #cyberattacks . Learn from the fallout of the Change Healthcare breach and plan for disaster. Read more: bit.ly/3y7CniY

.ASH experts express support for CAR T-cell therapy despite the ongoing investigation by the FDA into the development of secondary malignancies after its use. bit.ly/4d8DmPN #Hematology